Connection

Richard Silver to Treatment Outcome

Back to Details
This is a "connection" page, showing publications Richard Silver has written about Treatment Outcome.
Richard Silver
Connection Strength
0.255
Treatment Outcome
  1. Effect of orofacial exercises on oral aperture in adults with systemic sclerosis. Disabil Rehabil. 2012; 34(1):84-9.
    View in: PubMed
    Score: 0.042
  2. Effect of a multi-faceted intervention on gingival health among adults with systemic sclerosis. Clin Exp Rheumatol. 2011 Mar-Apr; 29(2 Suppl 65):S26-32.
    View in: PubMed
    Score: 0.041
  3. Outcome measures in the lung. Rheumatology (Oxford). 2008 Oct; 47 Suppl 5:v48-50.
    View in: PubMed
    Score: 0.034
  4. Neonatal alloimmune thrombocytopenia: antenatal management. Am J Obstet Gynecol. 2000 May; 182(5):1233-8.
    View in: PubMed
    Score: 0.019
  5. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016 09; 4(9):708-719.
    View in: PubMed
    Score: 0.015
  6. Secondary analysis of APPLE study suggests atorvastatin may reduce atherosclerosis progression in pubertal lupus patients with higher C reactive protein. Ann Rheum Dis. 2014 Mar; 73(3):557-66.
    View in: PubMed
    Score: 0.012
  7. The health education for lupus study: a randomized controlled cognitive-behavioral intervention targeting psychosocial adjustment and quality of life in adolescent females with systemic lupus erythematosus. Am J Med Sci. 2012 Oct; 344(4):274-82.
    View in: PubMed
    Score: 0.011
  8. Use of atorvastatin in systemic lupus erythematosus in children and adolescents. Arthritis Rheum. 2012 Jan; 64(1):285-96.
    View in: PubMed
    Score: 0.011
  9. Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus. Arthritis Rheum. 2010 Aug; 62(8):2467-75.
    View in: PubMed
    Score: 0.010
  10. Systemic sclerosis-associated interstitial lung disease-proposed recommendations for future randomized clinical trials. Clin Exp Rheumatol. 2010 Mar-Apr; 28(2 Suppl 58):S55-62.
    View in: PubMed
    Score: 0.010
  11. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis. 2009 May; 68(5):620-8.
    View in: PubMed
    Score: 0.009
  12. European League Against Rheumatism (EULAR) Scleroderma Trial and Research group (EUSTAR) recommendations for the treatment of systemic sclerosis: methods of elaboration and results of systematic literature research. Ann Rheum Dis. 2009 May; 68(5):629-34.
    View in: PubMed
    Score: 0.009
  13. A prospective, randomized, multicenter trial of amnioreduction vs selective fetoscopic laser photocoagulation for the treatment of severe twin-twin transfusion syndrome. Am J Obstet Gynecol. 2007 Oct; 197(4):396.e1-9.
    View in: PubMed
    Score: 0.008
  14. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med. 2007 Nov 15; 176(10):1026-34.
    View in: PubMed
    Score: 0.008
  15. Impact of oral cyclophosphamide on health-related quality of life in patients with active scleroderma lung disease: results from the scleroderma lung study. Arthritis Rheum. 2007 May; 56(5):1676-84.
    View in: PubMed
    Score: 0.008
  16. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006 Jun 22; 354(25):2655-66.
    View in: PubMed
    Score: 0.007
  17. Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience. Obstet Gynecol. 1992 Oct; 80(4):614-20.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.